(Q54050413)

24 May 2018

title

Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. (English)

1 reference

24 May 2018

1 reference

Lam XM

1

1 reference

24 May 2018

Duenas ET

2

1 reference

24 May 2018

Daugherty AL

3

1 reference

24 May 2018

Levin N

4

1 reference

24 May 2018

Cleland JL

5

1 reference

24 May 2018

language of work or name

English

0 references

publication date

1 July 2000

1 reference

24 May 2018

Journal of Controlled Release

published in

1 reference

24 May 2018

volume

67

1 reference

24 May 2018

issue

2-3

1 reference

24 May 2018

page(s)

281-292

1 reference

24 May 2018

Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

Evidence suggesting that the direct growth-promoting effect of growth hormone on cartilage in vivo is mediated by local production of somatomedin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

Brief report: treatment of insulin-resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

A month-long effect from a single injection of microencapsulated human growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

Factors affecting the in vitro release of recombinant human interferon-gamma (rhIFN-gamma) from PLGA microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

Controlled release of interleukin-2 from biodegradable microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

The stabilization and encapsulation of human growth hormone into biodegradable microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2800%2900224-8

7 January 2021

10.1016/S0168-3659(00)00224-8

Identifiers

DOI

1 reference

24 May 2018

1 reference

24 May 2018